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using two models of secondary brain tumours
Kate M Lewis, Elizabeth Harford-Wright, Robert Vink and Mounir N Ghabriel*Abstract
Background: Metastatic brain tumours are a common end stage of breast cancer progression, with significant
associated morbidity and high mortality. Walker 256 is a rat breast carcinoma cell line syngeneic to Wistar rats and
commonly used to induce secondary brain tumours. Previously there has been the assumption that the same
cancer cell line from different cell banks behave in a similar manner, although recent studies have suggested that
cell lines may change their characteristics over time in vitro.
Methods: In this study internal carotid artery injection and direct cerebral inoculation models of secondary brain
tumours were used to determine the tumorigenicity of Walker 256 cells obtained from two cell banks, the
American Type Culture Collection (ATCC), and the Cell Resource Centre for Medical Research at Tohoku University
(CRCTU).
Results: Tumour incidence and volume, plus immunoreactivity to albumin, IBA1 and GFAP, were used as indicators
of tumorigenicity and tumour interaction with the host brain microenvironment. CRCTU Walker 256 cells showed
greater incidence, larger tumour volume, pronounced blood–brain barrier disruption and prominent glial response
when compared to ATCC cell line.
Conclusions: These findings indicate that immortalised cancer cell lines obtained from different cell banks may
have diverse characteristics and behaviour in vivo.
Keywords: Walker 256 cells, Brain metastases, Breast cancer, Animal models, Blood–brain barrier, Tumour banks,
Glial reaction, TumorigenicityBackground
Cancer research has received much attention and fund-
ing over the past decades, reflecting its increased
incidence and significance as a public health problem.
Carcinogenesis is a multifaceted and complex disease
process, making malignancies inherently difficult to
treat, while at the same time presenting multiple path-
ways for investigation as management options. Novel
treatments targeting these different pathways can then
be assessed, although tumours in the brain have been
excluded from many clinical trials due to the restrictive
nature of the blood–brain barrier (BBB), often making
brain metastases not accessible to novel treatments* Correspondence: mounir.ghabriel@adelaide.edu.au
Adelaide Centre for Neuroscience Research, School of Medical Sciences, The
University of Adelaide, Adelaide, South Australia, Australia
© 2013 Lewis et al.; licensee BioMed Central L
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reproduction in any medium, provided the or[1,2]. Metastatic brain tumours are present in 22-30% of
patients diagnosed with breast cancer [3-5], therefore
making animal models of brain metastases important
tools to explore adequate treatment options for this as-
pect of the disease.
The process of brain metastases involves cells from a
primary tumour entering blood vessels, avoiding death
signals in the circulation, then undergoing extravasation
through the BBB [6]. The BBB is a dynamic interface be-
tween the cerebral circulation and brain tissue, and acts
to protect the brain microenvironment [7]. While inves-
tigating metastases, many scientists using cell culture
presume that tumour cell lines will behave indefinitely
in a uniform manner, although several studies have
demonstrated that this is not the case. Changes exhib-
ited with extended in vitro growth time, high passagetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 DNA Fingerprinting
Marker CRCTU Walker 256 ATCC Walker 256
Name Allele Allele
Size Size
1 97 97, 105
2 128, 130 128
3 163, 165, 183 163
4 238, 252 238, 252
42 155, 157 145
8 235, 239 235, 237
13 121, 123 121
15 248 245
16 251, 253, 273 243, 261
19 177, 179 177
24 250 259
26 159, 162, 171 152, 154
30 183, 187 187, 194
34 187, 189 187, 189
35 203, 209 203
36 224, 228 222
55 198, 206, 208 206
59 150 146
61 111 128
62 152, 155 167, 177
67 166 162
69 137, 148 139, 150
70 159, 170, 180 176
73 194, 200, 211 217
75 138, 144, 149 144, 184
78 153 151
79 172, 178, 184 172
81 130, 132 130
90 168, 172 162, 175
91 215, 222 211, 215
96 211, 213 211
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have been frequently described in the literature [8-11],
particularly when cancer cell lines are obtained from
sources other than reputable major cell libraries [12].
There is the assumption that well characterised cell lines
available from cancer cell repositories are verified and
maintained at a high standard, meaning that researchers
do not need to authenticate these cell lines before com-
mencing their experiments [13]. In the current study we
report differential characteristics of the same cancer cell
line obtained from two different reputable cell banks,
suggesting that researchers cannot assume that cells




The two Walker 256 cell lines from ATCC and the
CRCTU were compared using DNA fingerprinting and
shown to be of Sprague–Dawley rat origin without con-
tamination by cell lines of other mammalian species.
There is no existing reference DNA profile for the
Walker 256 cell line, so it is impossible to authenticate
the two cell populations used in this study. However,
when compared to each other the ATCC and CRCTU
Walker 256 cells had similar genetic profile with several
markers that theses cell populations had in common, al-
though many markers had different allele sizes (Table 1).
Cell morphology
In cell culture, both the Walker 256 cell populations
received from the CRCTU and the ATCC grew very ef-
fectively, although with very different cell morphology.
The cells from the CRCTU were small and spicular in ap-
pearance with deeply stained nuclei (Figure 1A), whereas
the cytoplasm of the ATCC cells was abundant and the
cells had a larger, flatter appearance with open face lighter
stained nuclei (Figure 1B). Nuclei of the two cell popula-
tions were comparable in size (Figure 1A and B). Both the
CRCTU and ATCC Walker 256 cell populations stained
positively for cytokeratin 18, a marker of breast cancer
cells (Figure 1A and B).
When the CRCTU and ATCC Walker 256 breast car-
cinoma cells were delivered to the brain through internal
carotid artery injection, the resultant tumours also
showed different cell morphology. The tumours from
CRCTU Walker 256 cells that grew 9 days following in-
ternal carotid artery injection showed cells with large
nuclei and scanty cytoplasm (Figure 1C). In contrast, the
single tumour that grew 10 weeks following internal ca-
rotid artery injection of ATCC Walker 256 cells showed
spindle-shaped cells with smaller nuclei and a larger
cytoplasmic component (Figure 1D). Furthermore, very
few mitotic figures in the ATCC tumour were seen,whereas CRCTU tumours exhibited several cells under-
going replication in any field of view (Figure 1C).
Tumorigenicity
The CRCTU Walker 256 cells grew much more aggres-
sively in vivo than the ATCC population as indicated by
the earlier sacrifice time required for the CRCTU
injected animals in both models. Following internal ca-
rotid artery injection, only one animal of 9 injected with
ATCC cells developed a metastatic brain tumour at the
10 week time point, whereas 8 out of the 9 animals
injected with the CRCTU cells showed tumours at the
Figure 1 Tumour cell morphology in vitro and in vivo. (A) CRCTU Walker 256 cells in culture stained for cytokeratin 18, showing spicular
appearance with deeply-stained nuclei. (B) ATCC Walker 256 cell in culture stained for cytokeratin 18 showing flattened cells with a large
cytoplasmic component and lightly stained nuclei and mitotic figures (arrows). (C) CRCTU Walker 256 tumour cell in vivo, 9 days following
internal carotid artery injection, stained with haematoxylin and eosin showing large nuclei and scanty cytoplasm with many mitotic figures
(arrows). (D) ATCC Walker 256 tumour cell in vivo, 10 weeks following internal carotid artery injection, showing smaller nuclei and abundant
elongated cytoplasmic component, giving the section an eosinophilic appearance.
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CRCTU internal carotid artery injected animals also
showed metastatic brain tumours in one out of the 5
animals killed at the intermediate time point of 6 days
following surgery (Table 2). Neither the CRCTU nor the
ATCC Walker 256 injected animals showed any evi-
dence of tumour growth at the early time point of 24
hours post internal carotid artery injection (Table 2).
The single tumour that resulted from carotid injection
with ATCC Walker 256 cells was located in the stri-
atum. In contrast, the tumour masses in the CRCTU
Walker 256 injected animals were predominantly found
in the lateral ventricles.
Similar to the internal carotid artery injection model,
the CRCTU cells were more effective in producing
metastatic brain tumours when inoculated directly into
the brain, compared to the ATCC cells (Table 2). DirectTable 2 Tumour incidence
Internal carotid artery i njection CRCTU
Early time point (n=5) 24 hours
Intermediate time point (n=5) 6 days
Late time point (n=9) 9 days
Direct inoculation CRCTU
(n=6) 7 days
Tumour incidence in animals injected via the internal carotid artery or directly inoc
Cell Resource Centre for Medical Research at Tohoku University (CRCTU) or the Ameinoculation of CRCTU tumour cells into the striatum
resulted in development of large neoplastic masses in
the brain tissue of 100% of the animals, whereas none of
the ATCC Walker 256 inoculated animals showed any
evidence of tumour growth (Table 2). Comparison of the
two models used in this study revealed that direct injec-
tion of CRCTU Walker 256 cells into the brain resulted
in larger and more consistent location of tumour growth
in the striatum with a mean volume of 55.28 mm3, com-
pared with an average tumour volume of 36.61mm3 fol-
lowing internal carotid artery injection of the same
CRCTU Walker 256 cells (Figure 2A and B).
All the animals that developed metastatic brain
tumours in the 9 day CRCTU group showed a concur-
rent growth of a tumour in the right eye (Figure 3A).
Also 44.4% of these animals had small tumour nodules
in the right temporalis muscle, and 33.3% developedATCC
0% (0/5) 24 hours 0% (0/5)
20% (1/5) 4 weeks 0% (0/5)
89% (8/9) 10 weeks 11% (1/9)
ATCC
100% (6/6) 4 weeks 0% (0/6)
ulated into the brain with Walker 256 breast tumour cells obtained from the
rican Type Culture Collection (ATCC).
Figure 2 Tumour volume. (A) Tumour volume following internal carotid artery injection with CRCTU and ATCC Walker 256 rat carcinoma cells
at 9 days and 10 weeks, respectively, following surgery showing. Only a single ATCC Walker 256 inoculated animal exhibited tumour growth
(*p<0.05). (B) Tumour volume following direct inoculation of CRCTU and ATCC cells into the right striatum 7 days and 4 weeks respectively
following surgery, only CRCTU Walker 256 inoculated animals grew metastatic brain tumours of substantial volume.
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were seen in the animals injected with ATCC Walker
256 cells, or with animals inoculated directly into the
striatum with the CRCTU Walker 256 cells.
Tumour interactions with the BBB
In the present study, albumin was used as an endogenous
marker of BBB permeability, given that serum albumin is
confined to blood vessels under normal conditions. How-
ever, when the BBB is compromised, albumin leaks out of
the blood vessels into the surrounding neuropil. Separate
control groups for different time points were required for
the direct inoculation model, due to the invasive nature of
the surgery. In contrast, injection of culture medium into
the internal carotid artery did not cause variation of
blood–brain barrier disruption over time, and only one
control group was used for all time points.
Neither CRCTU nor ATCC Walker 256 tumour injec-
tion into the internal carotid artery caused a significant
increase in albumin immunoreactivity 24 h following
surgery, when compared to the culture medium control
group (Figure 4A). A similar pattern of immunoreactiv-
ity was evident at the intermediate time point following
internal carotid artery injection of Walker 256 cells from
both cell banks (Figure 4A). In contrast, by 9 days follow-
ing CRCTU Walker 256 internal carotid artery injection
there was a significant increase in albumin immunoreac-
tivity in the brain coronal sections when compared to the
culture medium control group (p<0.001; Figure 4A). Simi-
larly, only CRCTU Walker 256 inoculated and not ATCC
Walker 256 inoculated brains showed a significant in-
crease in albumin immunoreactivity following direct injec-
tion of tumour cells into the striatum when compared to
the respective culture medium control group (p<0.001;
Figure 4B).
Widespread albumin immunoreactivity was evident
throughout the brains in animals that grew tumours
after receiving CRCTU Walker 256 cells by the internalcarotid artery injection or via direct inoculation into the
brain (Figure 4C). This indicates that the tumours that
result from CRCTU cell had widespread effects on BBB
permeability. In contrast, the increase in BBB perme-
ability was more concentrated in the immediate vicinity
of the single tumour that formed after ATCC Walker
256 tumour injection into the internal carotid artery
(Figure 4D).
Brain microenvironment
Both models of metastatic tumour induction caused
changes in the brain microenvironment when CRCTU
Walker 256 breast carcinoma cells were utilised (Figures 5
and 6). There was a significant increase in the number of
GFAP positive cells in the cortex of animals 9 days follow-
ing internal carotid artery injection of CRCTU Walker
256 cells when compared to the culture medium control
group (p<0.01; Figure 5A). Correspondingly, there was a
significant increase in the number of astrocytes immunos-
tained for GFAP in the striatum surrounding the tumour
mass 7 days following direct injection of CRCTU Walker
256 cells (p<0.01; Figure 5B). In contrast, ATCC Walker
256 cells administered via either the internal carotid artery
injection or direct inoculation into the striatum did not
significantly alter the number of GFAP labelled cells when
compared to the same location in culture medium inocu-
lated brains (Figure 5A, B).
GFAP immunoreactivity was absent within the tumour
masses for the CRCTU Walker 256 internal carotid ar-
tery model, indicating the absence of astrocytes within
the tumours (Figure 5C). However, the single tumour
that grew 10 weeks following internal carotid artery in-
jection of ATCC Walker 256 tumour cells showed an in-
crease in GFAP labelled cells in the peritumoral area
and some infiltrating labelled cells within the periphery
of the tumour (Figure 5D). The astrocytes surrounding
the tumour mass exhibited short, blunt, thickened pro-
cesses, with the flattened cells creating a limiting rim
Figure 3 Extracranial tumour growth. (A) CRCTU Walker 256
tumour growth (arrows) in the eye 9 days following internal carotid
artery injection stained with haematoxylin and eosin. (B) CRCTU
Walker 256 tumour growth (arrows) invading the temporalis muscle
9 days post internal carotid artery injection, stained with
haematoxylin and eosin. (C) Lung section stained with haematoxylin
and eosin, showing a large tumour mass (arrows) 9 days following
CRCTU Walker 256 cells carotid injection.
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ternal carotid artery injection of CRCTU Walker 256
cells within the lateral ventricles had limited contact
with the neuropil and lacked the GFAP positive astro-
cytic border that was evident around the ATCC Walker
256 tumour (Figure 5C).Tumour cell inoculation caused an increase in the num-
ber of microglia, as indicated by IBA1 labelling, in the cor-
tex of brains 9 days following internal carotid artery
injection of CRCTU Walker 256 cells in comparison to
control brains (Figure 6A). Similarly, 7 days after direct in-
jection of CRCTU Walker 256 cells into the brain, there
was a significant increase in IBA1 positive cells in the stri-
atum surrounding the tumour mass, when compared to
the same location in the culture medium control group
(p<0.01; Figure 6B). However, the increase in microglia
seen with CRCTU Walker 256 cell inoculation was not
replicated by ATCC Walker 256 cells when injected into
the internal carotid artery or inoculated directly into the
striatum (Figure 6A and B).
Examination of brain sections immunolabelled for IBA1
showed a distinct pattern of staining for each Walker 256
cell type. The CRCTU tumours showed sparse but specific
discrete labelling of infiltration by microglia (Figure 6C).
In contrast, the ATCC tumour showed more wides-
pread ill-defined labelling throughout the tumour mass
(Figure 6D). Furthermore, there was a halo of IBA1 la-
belled cells surrounding the tumour mass following in-
ternal carotid artery inoculation of ATCC Walker 256
cells, a feature that was not present surrounding the
CRCTU Walker 256 induced tumours (Figure 6C and D).
Discussion
In the current study, Walker 256 cells obtained from the
CRCTU had potent tumorigenic properties when com-
pared to the ATCC Walker 256 breast carcinoma cells.
Evidence of this includes the substantially increased inci-
dence of tumour growth and tumour volume after
CRCTU Walker 256 inoculation in the two tumour mod-
els used in this study, as well as the fact that only CRCTU
Walker 256 internal carotid artery injected animals devel-
oped tumours in the eye, temporalis muscle and lung. It
has been shown in previous studies that different tumour
cell lines cloned from the same neoplasm may have differ-
ent tumorigenic properties when implanted in vivo
[14,15]. However, cell lines developed from a single mouse
mammary tumour that showed differing culture morph-
ology and growth characteristics in vitro, resulted in
tumours that displayed similar histology to each other and
comparable tumorigenicity when injected into syngeneic
hosts [16].
Despite the fact that both populations of Walker 256
breast carcinoma cells were obtained from reputable
tumour cell banks that described the Walker 256 cell
line as tumorigenic in Wistar rats, there was consider-
able variability in their genetic profile and subsequently
growth behaviour in vivo and morphology in vitro. This
was despite the fact that both Walker 256 cell lines used
in this study were shown to be of rat origin with no evi-
dence of contamination by other mammalian cell lines.
Figure 4 Albumin immunoreactivity. (A) Graph showing %DAB in albumin immunostained coronal sections of the brain at early, intermediate
and late time points following internal carotid artery injection of CRCTU and ATCC Walker 256 tumour cells when compared to culture medium
control brains; ***p<0.001. (B) Graph showing %DAB in albumin immunostained brain coronal sections 7 days and 4 weeks following CRCTU and
ATCC Walker 256 tumour inoculation respectively, compared to culture medium control brains; ***p<0.001 (C) Coronal brain section stained for
albumin 9 days following internal carotid artery injection of CRCTU Walker 256 breast carcinoma cells showing widespread immunoreactivity
mainly in the right hemisphere. (D) Albumin immunostained brain coronal section 10 weeks post internal carotid artery injection with ATCC
Walker 256 breast carcinoma cells showing peritumoral immunoreactivity.
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standard method of cell line verification involving short
tandem repeat profiling along with the development of a
database of short tandem repeat profiles for commonly
used cell lines [17,18].
Control of cancer cell tumorigenicity has been exten-
sively studied, predominantly in relation to genetic con-
trol of cancer growth in vivo. For example, p75 has been
linked to reduced neuroblastoma tumorigenicity [19].
However, characteristics of tumour cells in culture have
also been investigated, with shorter doubling time,
reduced monolayer density, poor motility and lower in-
cidence of focus formation in vitro linked to decreased
tumorigenicity of cell lines when used in vivo [20,21], al-
though these experiments were generally comparing dif-
ferent cell lines. In contrast, the current study aimed to
determine the differences between the same cell line
obtained from two different sources.
The CRCTU Walker 256 breast carcinoma cells, found
to be more tumorigenic than their ATCC counterparts,
showed darker nuclear staining and increased nucleus to
cytoplasm ratio when compared to the flatter more eo-
sinophilic ATCC Walker 256 cells. There have been few
previous studies to determine the relationship between
cell morphology and cancer cell tumorigenicity. Furtherinvestigation is required to determine if the characteris-
tics observed in this experiment are related to the
tumorigenicity of the cells described. Furthermore, pre-
vious studies have suggested that behaviour of cancer
cell lines in vitro is poorly correlated with tumorigenicity
in vivo [21]. Despite this, in the current study morpho-
logical features seen in vitro for Walker 256 cells from
both the CRCTU and ATCC were closely associated
with the morphology evident in vivo.
There are many plausible explanations for the differen-
tial characteristics evident for CRCTU and ATCC Walker
256 breast carcinoma cells in this study. It is possible that
variations in storage methods, extended culture times and
high passage number may have contributed to the differ-
ences seen in the same cell line obtained from the CRCTU
and the ATCC. Immortalised tumour cell lines evolve over
time in animal models where malignancies are induced by
inoculation with a homogenous population of tumour
cells [22]. Conversely, human neoplastic tissue is not a
uniform entity. Within a tumour mass, there exist various
heterogeneous subpopulations of tumour cells with differ-
ent metastatic potential and diverse propensity to metasta-
sise to various organs [23,24].
Tumour cells harvested from a neoplasm in vivo have
been known to develop characteristics over time in vitro
Figure 5 GFAP immunoreactivity. (A) Graph showing the average number of GFAP positive cells in 4 areas of the cortex (0.0678 mm2) in
animals injected with culture medium, or injected with CRCTU or ATCC Walker 256 cells into the internal carotid artery; **p<0.01; *p<0.05.
(B) Graph showing the average number of GFAP positive cells in 4 areas of the striatum (0.0678 mm2) following direct inoculation of culture
medium, CRCTU or ATCC Walker 256 cells into the brain; **p<0.01. (C) GFAP immunostained section 9 days following CRCTU Walker 256 internal
carotid artery injection, showing absence of staining within the tumour, but showing GFAP labelled cell in peritumoral area (arrows). (D) Brain
section stained for GFAP 10 weeks following carotid ATCC Walker 256 tumour cell injection. Labelled astrocytes (arrows) are seen in the
peritumoral area and in the periphery of the tumour mass between the tumour cells. (E) High magnification of GFAP immunostained section 9
days following CRCTU Walker 256 internal carotid artery injection. (F) High magnification of GFAP immunostained section 10 weeks following
ATCC Walker 256 internal carotid artery injection. (G) GFAP immunostained section 7 days following direct inoculation of CRCTU Walker 256
inoculation showing substantial peritumoral immunoreactivity.
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ous tissue [14]. The proposed reason for this phenotypic
change is that more aggressive or mitotic properties are
favoured by clonal selection in vitro, with highly meta-
static varieties more phenotypically stable [25,26]. Long
term passage of Walker 256 cells has previously been
shown to alter chemotactic behaviour in vitro [27].
Walker 256 carcinoma is rat mammary tumour cell
line that originally occurred spontaneously in a pregnant
albino Sprague-Dawley rat [28]. The Walker 256 cell line
has been used previously to establish experimental brainmetastases through an internal carotid artery injection
and direct implantation into the cerebral cortex [29-33].
Tumour growth evident following both inoculation
methods of CRCTU Walker 256 cells showed larger
tumour volume in a shorter period of time, when com-
pared to previous experiments described in the literature
using the Walker 256 cell line, although the incidence
was comparable [34-37]. In contrast, the ATCC Walker
256 cells showed a much lower incidence and longer in-
cubation period required to form only a single tumour
when compared to these previous studies. Therefore,
Figure 6 IBA1 immunoreactivity. (A) The average number of IBA1 positive cells /0.0678 mm2 of the cortex in animals injected with culture
medium, CRCTU or ATCC Walker 256 breast carcinoma cells into the internal carotid artery. (B) The average number of IBA1 positive cells /0.0678
mm2 of the striatum following direct inoculation of culture medium, CRCTU or ATCC Walker 256 cells into the brain; **p<0.01. (C) IBA1
immunostained brain 9 days following internal carotid artery inoculation with CRCTU Walker 256 cells, arrows showing labelled cells dispersed
between cancer cells and in the peritumoral area. (D) IBA1 immunostained brain section showing extensive labelling within the tumour mass
(asterisk) and in the peritumoral area (arrows) 10 weeks following ATCC Walker 256 breast carcinoma cell injection into the internal carotid artery.
(E) Higher magnification IBA1 immunostained section 9 days following CRCTU Walker 256 internal carotid artery injection. (F) Higher
magnification IBA1 immunostained section 10 weeks following ATCC Walker 256 internal carotid artery injection. (G) IBA1 immunostained section
7 days following direct inoculation of CRCTU Walker 256 inoculation showing increased immunoreactivity in the peritumoral area along with IBA1
labelled cells within the tumour mass.
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carcinoma cells behaved exactly as previous studies have
described, although the CRCTU population were more
analogous to the literature.
Despite the consistency of the direct injection model
of tumour induction, the ATCC Walker 256 cells did
not grow any tumours through the use of this method.
Thus the extravasation process through the BBB is not
the limiting factor for ATCC Walker 256 tumour growth
in the brain. Furthermore, 11% of animals grew meta-
static brain tumours 10 weeks following ATCC Walker
256 inoculation into the internal carotid artery, meaningthat at least some of the tumour cells were able to
complete the extravasation process.
The CRCTU Walker 256 inoculated animals for both
the internal carotid artery and the direct inoculation
model showed a significant increase in albumin immu-
noreactivity when compared to the culture medium
group. It is likely that albumin immunoreactivity was
increased in response to the substantial tumour growth
evident in the CRCTU Walker 256 tumour inoculated
groups and subsequent increased BBB permeability. It is
well accepted in the literature that blood vessels within
brain metastases of breast cancer are more permeable
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breast tissue origin of the tumour cells causing substan-
tial cerebral oedema [29,38-41]. Furthermore, it has been
postulated that the permeability of blood vessels sur-
rounding brain metastases is also increased, which may
explain the widespread albumin immunoreactivity evi-
dent 9 days following CRCTU tumour injection into the
internal carotid artery.
The ATCC tumour cell inoculated animals only grew
one tumour in either model of metastatic brain tumour
induction, which was not sufficient to cause a significant
difference in albumin immunoreactivity from vehicle level
and thus did not increase the permeability of the BBB.
This shows that the presence of tumour cells with low
tumorigenicity in the brain microcirculation do not cause
an inflammatory reaction disrupts the normal function of
the BBB. Furthermore, ATCC Walker 256 localisation in
the neuropil of the striatum did not cause long term dam-
age to the brain sufficient to increase the permeability of
the BBB 4 weeks following direct injection.
A rim of reactive glial cells is often evident surrounding
metastatic brain tumours in human surgical tissue [42], as
was also apparent surrounding tumours grown in this
study. The pattern of glial cell reaction was different sur-
rounding CRCTU and ATCC Walker 256 tumours that
grew following internal carotid artery inoculation. The lo-
cation of CRCTU tumours within the lateral ventricles
may be the cause of these differences, as the mass is in less
direct contact with the neuropil. In contrast, the single
tumour that grew 10 weeks following internal carotid ar-
tery inoculation of ATCC Walker 256 cells, showed much
more extensive microglial infiltration along with increased
microglia and astrocytes surrounding the tumour. A pro-
posed function of this glial halo is to act as a barrier to the
flow of oedematous fluid [43]. Astrocytes and microglia
may proliferate and become activated in response to con-
tact with serum proteins, such as albumin which is
present in oedematous fluid that accumulates around the
tumour [33,44]. However it is also possible that in the dir-
ect inoculation model the glial reaction could be caused in
part by reaction to needle track injury, particularly for the
animals that were euthanized 7 days following CRCTU
Walker 256 inoculation.
The low tumorigenicity of ATCC Walker 256 cells
may be the reason that these cells did not show the
same influence on the brain microenvironment as
CRCTU Walker 256 growth. This is demonstrated by
the significant increase in IBA1 and GFAP labelled cells
following both internal carotid artery and direct injec-
tion of CRCTU Walker 256 tumour cells when com-
pared to the culture medium injected groups. However
this phenomenon was not evident following ATCC
Walker 256 tumour inoculation for either model used in
this study. Thus, the presence of low tumorigenicitycancer cells in the brain microcirculation or the neuro-
pil, did not show significant interaction with the host
microenvironment.
Conclusions
In conclusion, this study has demonstrated that the
Walker 256 tumour cells obtained from two reputable
sources have different tumorigenicity, growth character-
istics and interactions with the host brain. Such variabil-
ity should be considered when comparing studies using
the same cell line obtained from different sources.
Methods
Cell culture
Walker 256 breast tumour cells (rat) were obtained from
two cell banks, the American Type Culture Collection
(ATCC), and the Cell Resource Centre for Medical
Research at Tohoku University (CRCTU). The Walker
256 cells obtained from the ATCC were reported to be
passage number 290. However, the CRCTU did not pro-
vide details of passage number for the Walker 256 cells.
These two cell populations were cultured for a maximum
of 30 additional passages, in the same incubator. Both the
Walker 256 cell populations were cultured according to
the instructions from the respective cell bank. Briefly,
Walker 256 cells from ATCC were cultured in growth
medium consisting of Sigma 199 M4530 culture medium
containing 5% sterile normal horse serum and 1mL of
penicillin and streptomycin (Sigma 10,000 units of penicil-
lin and 10mg of streptomycin/mL) for each 100mL vol-
ume, while Walker 256 cells from the CRCTU were
cultured in growth medium made up of Sigma RPMI-
1640 culture medium containing 10% sterile foetal bovine
serum and 1 mL of penicillin and streptomycin (Sigma
10,000 units penicillin and 10 mg of streptomycin/mL) for
each 100 mL volume.
Culture flasks of 150 cm2 were used to grow the cells
and once >90% confluence was reached, the cells were
detached by the addition of 3.5 mL of 1% trypsin (Sigma)
or 3.5 mL of 0.02% EDTA for ATCC and CRCTU Walker
256 cells, respectively. The cells were spun down in a cen-
trifuge (5 minutes at 1500 RPM) and then resuspended in
serum free culture medium. The number of cells was cal-
culated using a haemocytometer and then diluted, so that
there was between 105 and 106 cells in every 0.2 mL of cell
suspension for internal carotid artery injection, or the
same number of cells in 8 μL for direct inoculation into
the brain.
Animals
The experimental procedures described throughout this
project were performed within the National Health and
Medical Research Council (NHMRC) guidelines and were
approved by both the University of Adelaide and Institute
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Committees. All experiments complied with the EC
Directive 86/609/EEC for animal experiments. Male
Wistar rats weighing 250-350 g were group housed in
the IMVS Animal Facility and were supplied with a diet
of rodent pellets and water ad libitum. Animals were
randomly selected for either the internal carotid injec-
tion procedure or the direct inoculation procedure and
then were further divided into culture medium only
control group, Walker 256 tumour CRCTU group and
Walker 256 tumour ATCC group.
DNA fingerprinting of cell lines
The Walker 256 cell lines obtained from the CRCTU
and ATCC were submitted to IDEXX RADIL for DNA
fingerprinting, using 31 short tandem repeat markers
that are rat specific in order to establish the genetic pro-
file of the two cell populations. Cell samples were also
tested for cross species contamination.
Internal carotid artery injection
Animals allocated to the internal carotid injection pro-
cedure were sacrificed at 24 h (early, n=5), 6 days (inter-
mediate, n=5) and 9 days (late, n=9) for the CRCTU
Walker 256 cells, and at 24 h (early, n=5), 4 weeks
(intermediate, n=5) and 10 weeks (late, n=9) for the
ATCC Walker 256 cells. The selected late time points
were determined after a pilot study of tumour burden
and animal weight loss for both cell lines. The method
for internal carotid artery injection of tumour cells to
induce metastatic brain tumour growth has been previ-
ously described in detail [45]. Briefly, under 2% isoflur-
ane inhalation anaesthesia via endotracheal tube, a
longitudinal skin incision was made to expose the ca-
rotid bifurcation. The ophthalmic artery, superior thy-
roid artery and pterygopalatine artery were occluded to
specifically deliver tumour cells to the brain. The exter-
nal carotid artery was sacrificed, forming a surgical
stump to provide an access point for cannulation of the
internal carotid artery for injection of 0.2 mL of culture
medium or tumour cell suspension, following temporary
occlusion of the common carotid artery. Once the can-
nula was removed and a suture tied around the external
carotid stump, blood flow through the common carotid
artery was re-established and the wound sutured.
Direct inoculation
Animals that received direct intraparenchymal inocula-
tion were sacrificed at 7 days and 4 weeks for the
CRCTU and ATCC Walker 256 cells, respectively (n=6/
group). Direct stereotaxic inoculation of tumour cells
into the right striatum for induction of metastatic brain
tumour has been previously described in detail [46].
Briefly, animals were anaesthetised using 3% isofluraneinhalation anaesthesia via a nose cone, placed in a stereo-
tactic frame and a midline scalp incision made to expose
the skull. A 0.7mm burr hole was performed at stereo-
taxic coordinates: anterior 0.5 mm, lateral 3 mm to the
right relative to the bregma. A 30 gauge Hamilton syringe
was inserted and lowered stereotaxically 5mm and 8 μL of
culture medium or tumour cell suspension injected dir-
ectly into the brain tissue over 10 minutes. 5 minutes fol-
lowing inoculation, the needle was removed, the hole was
sealed with bone wax and the wound sutured.
Tumour volume
For histological analysis, animals were transcardially per-
fused with 10% formalin under terminal anaesthesia
induced by intraperitoneal administration of pentobarbit-
one sodium (60 mg/kg). Brains were embedded in paraffin
wax and sequential 5 μm coronal sections were cut from
blocks 2mm thick in a rostro-caudal direction, to be used
for haematoxylin and eosin staining and immunohisto-
chemistry. The haematoxylin and eosin stained slides were
scanned using a Nanozoomer (Hamamatsu, Hamamatsu
City, Japan) and images used to calculate tumor volume.
This was performed by determining the area of tumour in
each section using the NDP viewer programme and multi-
plying the area by the distance between sections as previ-
ously described [47].
Immunostaining
Slides from each model were stained for albumin (ICN
Pharmaceuticals, 1:20,000), glial fibrillary acidic protein
(GFAP, Dako, 1:40,000) and ionized calcium binding
adaptor molecule 1 (IBA1, Dako, 1:50,000). Tumour
cells were also grown on cover-slips in vitro to be
immunostained for cytokeratin18 (Gene Tex, 1:3,000).
Immunohistochemistry was performed using the stand-
ard streptavidin procedure with 3,30-diaminobenzidine
(DAB) for visualization and haematoxylin counters-
taining. Slides were scanned using the Nanozoomer.
Albumin immunostaining, expressed as the weighted %
DAB in each coronal section, was estimated using
colour deconvolution techniques, as described previ-
ously [48,49]. For GFAP and IBA1 immunoreactivtiy, 4
fields of view were taken from the cortex and striatum
for the internal carotid artery injection model and the
direct inoculation model. The immunolabelled cells in
these images were counted and the mean number calcu-
lated for all images from each brain.
Statistical analysis
Results were expressed as mean±SEM and an unpaired t
test (for two groups) or a one-way analysis of variance
followed by a Bonferroni post test (for more than two
groups) performed. Values of p<0.05 were designated as
significant.
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